Announcements
Botulinum toxin
Allergan, Solistice Neurosciences and Ipsen are alerting health care
professionals to safety information regarding botulinum toxin products.
Serious adverse events related to the distant spread of botulinum toxin
(including muscle weakness, dysphagia and aspiration) have been reported
with all botulinum toxin products.
There is a need for extreme caution
when administering botulinum toxin products to patients with neurological
disorders or a history of dysphagia or aspiration. Patients and caregivers
should be informed about the risk of toxins spreading and be advised
to seek immediate medical care if swallowing, speech or respiratory
disorders arise.
Botulinum toxin units are not interchangeable from one
product
to another. |
The
Pharmaceutical Journal